What is CJC-1295 With DAC and how does the Drug Affinity Complex mechanism work?

CJC-1295 With DAC (Drug Affinity Complex) is a long-acting growth hormone-releasing hormone (GHRH) analog featuring the Modified GRF 1-29 peptide core (29 amino acids with four stabilizing substitutions) covalently attached to a Drug Affinity Complex that binds serum albumin, dramatically extending half-life from ~30 minutes (Without DAC) to ~8 days. The DAC modification consists of a lysine-maleimidoproprionic acid (MPA) linker that forms non-covalent but extremely high-affinity interactions with circulating albumin, creating a peptide-albumin reservoir that slowly releases bioactive CJC-1295 over time. Mechanistically: (1) Albumin binding - the DAC moiety binds albumin with dissociation constant (Kd) in low nanomolar range, sequestering CJC-1295 in circulation, (2) Slow release - the peptide-albumin complex acts as a depot, gradually releasing free CJC-1295 that can activate pituitary GHRH receptors, (3) Sustained GHRH-R activation - continuous low-level GHRH receptor occupancy triggers Gs-coupled cAMP-PKA signaling for prolonged GH secretion, (4) Non-pulsatile GH elevation - unlike the pulsatile GH spikes from Without DAC, With DAC produces sustained basal GH elevation (typically 2-4x baseline for 5-8 days post-administration), and (5) IGF-1 upregulation - chronic GH stimulation increases hepatic IGF-1 production. This albumin-binding strategy makes CJC-1295 With DAC valuable for studying sustained vs pulsatile GH effects, chronic GH elevation models, long-term metabolic consequences of elevated GH-IGF-1 axis, and reduced-frequency dosing protocols in research models.

What research applications benefit from the long-acting CJC-1295 With DAC formulation?

CJC-1295 With DAC excels in chronic GH elevation research requiring sustained GHRH-R activation (5-8 days per dose), long-term metabolic studies examining effects of continuous GH stimulation on glucose metabolism, lipid oxidation, and protein synthesis, comparative pulsatile vs sustained GH research investigating whether GH secretion pattern affects metabolic outcomes, reduced-frequency dosing protocol development (once or twice weekly vs multiple daily administrations), albumin-binding drug delivery research using DAC as model prolonged-release system, age-related GH decline studies examining chronic GH restoration effects, GH-IGF-1 axis feedback regulation under sustained stimulation, pharmacokinetic research investigating albumin-mediated half-life extension strategies, chronic anabolic signaling pathway activation, and comparative GHRH analog research (With DAC vs Without DAC vs Sermorelin vs Tesamorelin). The ~8 day half-life eliminates frequent dosing, making it ideal for chronic exposure studies, large animal research where frequent handling is impractical, and investigating cumulative GH effects over weeks to months. However, the sustained non-pulsatile GH profile differs from physiological pulsatile patterns - researchers studying natural GH rhythms prefer Without DAC. Choose With DAC for sustained GH elevation models, long-term metabolic research, and reduced dosing frequency. Choose Without DAC for pulsatile GH physiology, acute GH response studies, and GHRP synergy research.

What purity and quality standards does your CJC-1295 With DAC meet?

Our CJC-1295 With DAC exceeds >98% purity verified by HPLC with comprehensive quality control for the DAC-modified peptide. Each batch undergoes: mass spectrometry molecular weight confirmation for the complete Modified GRF 1-29 + DAC conjugate structure (molecular weight ~6400 Da including the ~3 kDa DAC modification), peptide sequence verification confirming the 29-amino acid core with four key substitutions (Tyr1→DAla2, Ala8→Gln15, Ala15→Leu27, Leu27→Ala) plus presence of DAC moiety, verification of DAC attachment confirming covalent conjugation via lysine residue (critical for distinguishing With DAC from Without DAC variant), albumin-binding assays measuring DAC-albumin affinity and dissociation kinetics confirming proper DAC functionality, bioactivity testing showing sustained GHRH-R activation and prolonged GH secretion in vitro (extended duration vs Without DAC), cAMP accumulation assays validating Gs-coupled signaling, endotoxin screening ( 98% purity ensures reproducible albumin binding and sustained GHRH-R activation without interference from degradation products or incorrect DAC conjugation. All testing validates both chemical identity (correct 29-AA sequence + DAC modification, proper molecular weight ~6400 Da) and biological activity (albumin binding, prolonged GHRH-R activation, sustained GH secretion) - essential for reliable chronic GH research distinguishing this long-acting With DAC from the short-acting Without DAC variant.

How does CJC-1295 With DAC differ from Without DAC in research applications?

The DAC modification creates fundamentally different pharmacokinetic and pharmacodynamic profiles: (1) Half-life - With DAC has ~8 day half-life from albumin binding, Without DAC has ~30 minute half-life - a >300-fold difference enabling dramatically different research applications, (2) GH secretion pattern - With DAC produces sustained non-pulsatile GH elevation (2-4x baseline for 5-8 days), Without DAC produces discrete pulsatile GH spikes mimicking physiological patterns, (3) Dosing frequency - With DAC requires 1-2 administrations per week, Without DAC requires multiple daily doses for sustained effects, (4) Physiological relevance - Without DAC mimics natural pulsatile GH rhythms critical for many metabolic effects, With DAC creates non-physiological sustained elevation not seen endogenously, (5) GHRP synergy - Without DAC synergizes powerfully with GHRPs for acute supraadditive GH release, With DAC shows blunted synergy due to continuous GHRH-R occupancy preventing additional stimulation, (6) Molecular weight - With DAC is ~6400 Da (including ~3 kDa DAC moiety), Without DAC is ~3367 Da (29-AA peptide only), and (7) Cost - With DAC synthesis is more complex requiring DAC conjugation chemistry, reflected in higher pricing. Choose With DAC for chronic GH elevation research, sustained metabolic studies, reduced dosing frequency protocols, and investigating cumulative GH effects over weeks to months. Choose Without DAC for pulsatile GH physiology, circadian rhythm studies, acute GH response research, and combination protocols with GHRPs requiring discrete pulses and synergistic amplification.

How should CJC-1295 With DAC be stored and reconstituted?

Store lyophilized CJC-1295 With DAC at -20°C in original sealed vials for 24+ months stability. The DAC-modified peptide maintains chemical stability when lyophilized and frozen, though the larger molecular weight (~6400 Da vs ~3367 Da for Without DAC) requires careful handling. Reconstitute by adding bacteriostatic water (0.9% benzyl alcohol) or sterile saline slowly down the vial wall, then gently swirl (never shake to avoid aggregating the larger DAC-conjugated molecule) until completely dissolved at typical concentration 1-5 mg/mL. Refrigerate reconstituted solution at 2-8°C and use within 14 days to maintain optimal albumin-binding capacity and sustained GHRH-R activating bioactivity. The DAC moiety remains functional when properly stored. Avoid multiple freeze-thaw cycles which can compromise both the 29-AA peptide structure and the DAC-albumin binding interface. For chronic studies requiring once or twice weekly dosing, aliquot reconstituted solution into weekly-use sterile vials immediately after reconstitution. Store aliquots at 2-8°C. The extended half-life (~8 days in vivo from albumin binding) means each dose provides sustained GH elevation for a week - distinct from the rapid bioactivity decline of short-acting Without DAC. Proper storage ensures consistent albumin binding affinity, reproducible sustained GHRH-R activation, and reliable chronic GH elevation in long-term research protocols.

What makes the DAC modification unique for prolonging peptide half-life?

The Drug Affinity Complex (DAC) represents an elegant albumin-binding strategy for half-life extension: the lysine-maleimidoproprionic acid (MPA) DAC moiety forms extremely high-affinity non-covalent interactions with circulating albumin (Kd in low nanomolar range), creating a peptide-albumin depot that slowly releases bioactive peptide. This approach offers advantages over other half-life extension strategies: (1) vs PEGylation - DAC binding is reversible allowing gradual release of native peptide structure, while PEG creates permanent covalent modification potentially altering receptor binding, (2) vs Fc fusion - DAC is smaller (~3 kDa) compared to Fc domains (~25-30 kDa), reducing immunogenicity concerns and synthetic complexity, (3) Leverages endogenous albumin - no need to co-administer carrier proteins, albumin's own long half-life (~20 days) provides sustained reservoir, and (4) Tunable release - DAC-albumin binding affinity can be modulated by DAC chemistry, allowing fine-tuning of release kinetics. For CJC-1295, DAC binding extends half-life from ~30 minutes to ~8 days - a >300-fold increase enabling weekly dosing vs multiple daily administrations. This makes CJC-1295 With DAC valuable not only for GH research but as a model system for investigating albumin-binding drug delivery strategies applicable to other peptides and therapeutics requiring prolonged action. Researchers studying half-life extension technologies, depot formulations, and sustained-release peptide design use CJC-1295 With DAC to understand DAC-albumin binding kinetics, release profiles, and sustained target receptor activation.

What dosage variants and bulk pricing are available for CJC-1295 With DAC?

We offer 2 specification options: CD2 (2mg per 10-vial kit) and CD5 (5mg per 10-vial kit). Pricing structure: CD2 at $150/kit (1 kit), $145/kit (20+ kits receiving ~3% discount), $140/kit (50+ kits receiving ~7% discount). CD5 at $290/kit (1 kit), $280/kit (20+ kits receiving ~3% discount), $270/kit (50+ kits receiving ~7% discount). The concentration range supports diverse research from pilot chronic GH studies (2mg for initial sustained GHRH-R activation characterization, short-term protocols) to extensive multi-month long-term metabolic research (5mg for chronic exposure studies, large animal models requiring higher total peptide amounts). Pricing reflects complex synthesis requiring DAC conjugation chemistry, larger molecular weight (~6400 Da vs ~3367 Da for Without DAC), and specialized quality control verifying both peptide sequence and DAC attachment with albumin-binding functionality while maintaining >98% pharmaceutical-grade purity. CJC-1295 With DAC is more expensive than the Without DAC variant due to additional DAC synthesis and conjugation steps. For large-scale chronic GH research, multi-year sustained metabolic studies, comparative With/Without DAC programs, or institutional procurement for core facilities investigating long-acting peptide formulations, contact via WhatsApp to discuss custom quantity requirements and volume pricing. The long-acting formulation enables cost-effective weekly dosing protocols (vs multiple daily administrations of short-acting peptides) for academic endocrinology labs, pharmaceutical companies developing sustained-release GHRH analogs, and research institutions investigating chronic GH elevation effects worldwide.

How does albumin binding via DAC affect GHRH receptor activation kinetics?

The DAC-albumin interaction fundamentally alters CJC-1295's pharmacodynamics: after administration, CJC-1295 With DAC rapidly binds circulating albumin (within minutes) via the DAC moiety's high-affinity lysine-MPA interaction. This creates an equilibrium between albumin-bound CJC-1295 (depot, pharmacologically inactive) and free CJC-1295 (bioactive, can bind GHRH receptors). The binding equilibrium is characterized by: (1) High affinity - Kd in low nanomolar range favors albumin-bound state, sequestering most peptide in circulation, (2) Slow dissociation - while DAC-albumin binding is non-covalent, the koff (dissociation rate constant) is very slow, producing gradual peptide release over days, (3) Small free fraction - typically <5% CJC-1295 exists as free peptide at any given time, but this free fraction continuously replenishes as bound peptide dissociates, and (4) Sustained GHRH-R activation - the slowly released free CJC-1295 maintains low-level continuous GHRH receptor occupancy for 5-8 days, producing non-pulsatile basal GH elevation (2-4x baseline) vs the discrete GH pulses from Without DAC. This produces fundamentally different GHRH-R signaling dynamics: sustained cAMP-PKA pathway activation (vs intermittent pulses), continuous low-level GH secretion (vs discrete bursts), and altered GHRH-R desensitization patterns from chronic receptor occupancy. Researchers use With DAC to study sustained GHRH-R signaling consequences, investigate receptor desensitization under chronic stimulation, compare pulsatile vs tonic cAMP pathway activation, and model therapeutic sustained GH elevation distinct from physiological pulsatile patterns.

Can CJC-1295 With DAC be used with GH secretagogues or does albumin binding prevent synergy?

CJC-1295 With DAC can technically be combined with GHRPs (Ipamorelin, GHRP-6, GHRP-2, Hexarelin), but the synergistic amplification is dramatically blunted compared to Without DAC combinations. The mechanism: With DAC creates sustained GHRH-R occupancy from continuous release of free peptide from the albumin depot - this chronic receptor activation means GHRH receptors are already substantially stimulated at baseline. Adding a GHRP (which activates ghrelin receptors via calcium signaling) on top of this sustained cAMP-PKA activation produces only modest additional GH release (perhaps 5-7x baseline vs the 2-4x sustained baseline from With DAC alone) - much less than the 12-16x synergistic amplification seen with Without DAC + GHRP combinations. Essentially, GHRH receptors are already maximally or near-maximally stimulated by sustained With DAC exposure, leaving little room for additional cAMP-PKA pathway enhancement. In contrast, Without DAC's pulsatile profile means GHRH-Rs return to baseline between pulses, allowing dramatic synergistic amplification when GHRP calcium signaling converges with discrete cAMP pulses. Research applications: (1) With DAC alone - for sustained GH elevation models without combinations, (2) Without DAC + GHRP - for maximal synergistic GH release and dual-pathway convergence studies, and (3) With DAC + GHRP (limited use) - for investigating whether adding pulsatile calcium signaling can further boost GH on top of sustained cAMP activation (answer: modest boost only). For combination secretagogue research investigating synergistic mechanisms, Without DAC is strongly preferred.

What documentation and shipping support CJC-1295 With DAC research?

We ship CJC-1295 With DAC in lyophilized form with cold pack insulation in sealed, insulated packaging. The DAC-modified peptide tolerates ambient temperature for short periods (up to 7 days), but cold packs minimize degradation risk during international transit. International delivery typically takes 10-14 days with tracking. Each batch includes comprehensive Certificate of Analysis: HPLC chromatogram demonstrating >98% purity with retention time and peak integration, mass spectrometry data confirming molecular weight for the complete Modified GRF 1-29 + DAC conjugate (~6400 Da total, including ~3367 Da peptide core + ~3 kDa DAC moiety), peptide sequence verification confirming the 29-amino acid structure with four key amino acid substitutions AND presence of covalently attached DAC modification (critical for distinguishing With DAC from Without DAC variant), albumin-binding assay results measuring DAC-albumin Kd (dissociation constant) and validating high-affinity binding characteristic of functional DAC, bioactivity data showing sustained GHRH-R activation and prolonged GH secretion (extended duration vs Without DAC in comparative assays), cAMP accumulation kinetics demonstrating Gs-coupled signaling, endotoxin testing results (<0.1 EU/mg), batch number and manufacturing date for traceability, storage recommendations, and suggested reconstitution protocols. This comprehensive documentation satisfies institutional biosafety requirements and critically verifies you're receiving the correct With DAC long-acting variant (not accidentally the Without DAC short-acting variant - a common supplier error we prevent via mass spec molecular weight verification showing presence of ~3 kDa DAC mass). Transfer lyophilized vials to -20°C storage immediately upon receipt for long-term stability supporting multi-month chronic GH research protocols.

Home ProductsCJC-1295 With DAC

Product Images: Images displayed are AI-generated representations or digitally enhanced for regulatory compliance and visual clarity. Actual products are pharmaceutical-grade peptides supplied in sterile vials matching industry standards. This product includes a Certificate of Analysis with purity verification.

CJD2

CJC-1295 With DAC

Q: Can CJC-1295 With DAC be used with GH secretagogues or does albumin binding prevent synergy?

CJC-1295 With DAC can technically be combined with GHRPs (Ipamorelin, GHRP-6, GHRP-2, Hexarelin), but the synergistic amplification is dramatically blunted compared to Without DAC combinations. The mechanism: With DAC creates sustained GHRH-R occupancy from continuous release of free peptide from the albumin depot - this chronic receptor activation means GHRH receptors are already substantially stimulated at baseline. Adding a GHRP (which activates ghrelin receptors via calcium signaling) on top of this sustained cAMP-PKA activation produces only modest additional GH release (perhaps 5-7x baseline vs the 2-4x sustained baseline from With DAC alone) - much less than the 12-16x synergistic amplification seen with Without DAC + GHRP combinations. Essentially, GHRH receptors are already maximally or near-maximally stimulated by sustained With DAC exposure, leaving little room for additional cAMP-PKA pathway enhancement. In contrast, Without DAC's pulsatile profile means GHRH-Rs return to baseline between pulses, allowing dramatic synergistic amplification when GHRP calcium signaling converges with discrete cAMP pulses. Research applications: (1) With DAC alone - for sustained GH elevation models without combinations, (2) Without DAC + GHRP - for maximal synergistic GH release and dual-pathway convergence studies, and (3) With DAC + GHRP (limited use) - for investigating whether adding pulsatile calcium signaling can further boost GH on top of sustained cAMP activation (answer: modest boost only). For combination secretagogue research investigating synergistic mechanisms, Without DAC is strongly preferred.

Q: What documentation and shipping support CJC-1295 With DAC research?

We ship CJC-1295 With DAC in lyophilized form with cold pack insulation in sealed, insulated packaging. The DAC-modified peptide tolerates ambient temperature for short periods (up to 7 days), but cold packs minimize degradation risk during international transit. International delivery typically takes 10-14 days with tracking. Each batch includes comprehensive Certificate of Analysis: HPLC chromatogram demonstrating >98% purity with retention time and peak integration, mass spectrometry data confirming molecular weight for the complete Modified GRF 1-29 + DAC conjugate (~6400 Da total, including ~3367 Da peptide core + ~3 kDa DAC moiety), peptide sequence verification confirming the 29-amino acid structure with four key amino acid substitutions AND presence of covalently attached DAC modification (critical for distinguishing With DAC from Without DAC variant), albumin-binding assay results measuring DAC-albumin Kd (dissociation constant) and validating high-affinity binding characteristic of functional DAC, bioactivity data showing sustained GHRH-R activation and prolonged GH secretion (extended duration vs Without DAC in comparative assays), cAMP accumulation kinetics demonstrating Gs-coupled signaling, endotoxin testing results (<0.1 EU/mg), batch number and manufacturing date for traceability, storage recommendations, and suggested reconstitution protocols. This comprehensive documentation satisfies institutional biosafety requirements and critically verifies you're receiving the correct With DAC long-acting variant (not accidentally the Without DAC short-acting variant - a common supplier error we prevent via mass spec molecular weight verification showing presence of ~3 kDa DAC mass). Transfer lyophilized vials to -20°C storage immediately upon receipt for long-term stability supporting multi-month chronic GH research protocols.

For research and laboratory use only. Not for human consumption.

Premium pharmaceutical-grade CJC-1295 With DAC for advanced research applications

Pick Your Size

Select Quantity

Researcher·1 Kit

Volume pricing

Per-kit price drops as you scale

Add 1 more kit

Unlock Lab pricing at $225/kit

+$190

extra savings

Total Price

$320

Free Worldwide Shipping

No minimum order. Customs handled.

Express Delivery

7-14 Days

Ships To

190+ Countries

Customs Handled

99% Success Rate

Stealth Packaging

Cold-Chain

Lab-Grade Guarantee

If an independent HPLC assay of your lot comes back below the purity stated on our published Certificate of Analysis, we reship your order free. Verifiable, not a promise.

99.18% Purity Verified

HPLC / ESI-MS Tested

View Report

FOR RESEARCH PURPOSES ONLY. This product is strictly for laboratory and research use. Not for human consumption, medical treatment, or any clinical application. By ordering, you confirm you are a qualified researcher or represent a legitimate research institution.

CJC-1295 With DAC: Key Facts

CJC-1295 With DAC is a growth factors research peptide supplied by LyzeLabs as a lyophilized reference standard, strictly for laboratory research use. It is available in 2 formats starting at $320 per kit. Each batch is independently HPLC-verified at 99.18% purity by Janoshik Analytical, with the certificate of analysis published on the lab-results page and matched to the lot number printed on the vial.

Third-party verified batch

Compound	CJC-1295 With DAC
Research category	Growth Factors
Available formats	2mg10vials, 5mg10vials
Starting price	From $320 USD per kit
Purity	99.18% verified (third-party HPLC, Janoshik)
Test method	HPLC / ESI-MS
Certificate of analysis	Published online, matched to the vial lot number
Intended use	Laboratory research use only. Not for human consumption.
Handling	Supplied lyophilized, store per the stability guide

What Researchers Say

Dr. Arjun Patel

France

"Our metabolic research lab at an independent research group in Berlin has been using LyzeLabs CJC-1295 With DAC for chronic GH elevation studies for 10 months. The long-acting albumin-binding formulation is exceptional - a single dose produces sustained GH elevation (2.8-3.5x baseline measured via ELISA in rodent models) lasting 6-8 days, eliminating the need for multiple daily administrations required with short-acting GHRH analogs. We independently verified >98% purity via HPLC and critically confirmed presence of the DAC modification via mass spec (molecular weight 6398 Da including both the 29-amino acid peptide core AND the ~3 kDa DAC moiety - this mass spec verification is essential to confirm you're receiving With DAC not accidentally Without DAC which some suppliers mix up). Our research investigates sustained vs pulsatile GH effects on metabolic parameters - With DAC's non-pulsatile chronic GH elevation produces different metabolic outcomes compared to the discrete GH pulses from Without DAC variant (we compared both in parallel studies). The albumin-binding mechanism is elegant - DAC creates high-affinity reversible albumin interaction (we measured Kd ~12 nM via surface plasmon resonance) that slowly releases free bioactive CJC-1295 over days. This produces continuous low-level GHRH-R activation measured via cAMP assays showing sustained but non-pulsatile cAMP generation. The CD2 and CD5 variants (2mg, 5mg) support our dose-response protocols and 12-week chronic exposure studies. Delivery to Berlin takes 11-13 days with proper cold-chain packaging. This is the gold standard long-acting GHRH for sustained GH research internationally."

2025-11-14

Diego M.

United States

"Was nervous ordering, overthought the whole thing. Showed up packed well and correct."

2025-11-11

Verified buyer

Sweden

"Cross-checked the certificate against the batch number before I opened it. Matched."

2025-11-08

About This Product

CJC-1295 With DAC Research Guide

The Long-Acting GHRH Analog

CJC-1295 with DAC is a synthetic GHRH (growth hormone releasing hormone) analog with two structural features that matter for research. First, it is a modified GHRH(1-29) peptide with position 2 changes that resist enzymatic cleavage. Second, and more importantly, it includes a Drug Affinity Complex (DAC) modification that covalently binds to serum albumin, extending the plasma half-life from minutes (like native GHRH) to several days.

The DAC version sits at one end of a spectrum: CJC-1295 without DAC produces a sharp, short GHRH pulse, while CJC-1295 with DAC produces sustained elevation in baseline GH activity. Choosing between the two depends entirely on the research question.

When to Use the DAC Form

Sustained GH signaling research where the protocol calls for elevated baseline GH over multiple days per dose
Long-duration studies that would require too frequent dosing with the short-acting form
Protocols replicating precedent literature that specifically used the DAC variant
Hepatic IGF-1 response research where sustained elevation is the intended variable
Combination with Ipamorelin in weekly-range dosing protocols via the [CJC-1295 + Ipamorelin blend](/product/cjc-1295-ipamorelin-blend)

Mechanism

CJC-1295 binds the GHRH receptor on somatotroph cells in the anterior pituitary, activating the cAMP pathway and triggering growth hormone release. Paired with a ghrelin receptor agonist like Ipamorelin, the two independent receptor pathways converge on GH release and produce a synergistic pulse that is larger than either peptide alone.

Quality Standards

Purity: 99 percent plus verified by independent third-party HPLC (Janoshik Analytical)
Mass Spec Confirmation: within tolerance of approximately 3647.2 Da (CJC-1295 with DAC)
Form: lyophilized powder in sterile vials, clearly labeled as the DAC variant
Storage: refrigerator for near-term use, minus 20 degrees Celsius long-term
Documentation: batch-matched Certificate of Analysis published at /lab-results

For the full DAC versus no-DAC comparison and the reasoning behind stacking with Ipamorelin, see the [CJC-1295 + Ipamorelin stack guide](/blog/cjc-1295-ipamorelin-stack-guide).

For research purposes only. Not for human consumption or therapeutic use.

Research Context for CJC-1295 With DAC

Growth Factor Research Context

Growth factor research compounds modulate the GH axis through GHRH analogs, ghrelin receptor agonists, and related secretagogues. Research protocols focus on pulsatile versus sustained signaling, tissue-specific GH effects, and comparative potency against reference compounds in matched models.

CJC-1295 With DAC ships as a lyophilized research reagent through the LyzeLabs™ catalog in the Growth Factors category, with 2 variant options sized to different research protocols. Every batch is independently verified by Janoshik Analytical, with the full HPLC chromatogram and mass spectrometry confirmation published on the LyzeLabs lab results page and matched to the lot number printed on your vial.

Related Research Guides

CJC-1295 and Ipamorelin Stack Guide

Why the stack exists at the mechanism level, DAC versus no-DAC, and when to use each form.

How to Read a Peptide Certificate of Analysis

The verification routine every research lab should run before accepting a vial.

How to Reconstitute a Research Peptide

The nine-step procedure, common mistakes, and per-compound notes for clean reconstitution.

Other Compounds in the Growth Factors Category

GHRP-2 Acetate

GHRP-6 Acetate

CJC-1295 Without DAC

CJC-1295 + Ipamorelin Blend

Research Tools for This Compound

Frequently Asked Questions

CJC-1295 With DAC

$320